What is the recommended treatment for urticarial vasculitis?

Urticarial Vasculitis Treatment

For urticarial vasculitis, start with H1-antihistamines and escalate to systemic corticosteroids for more severe disease, reserving biologics (particularly omalizumab, rituximab, or IL-1 inhibitors) and immunomodulators for refractory cases that fail conventional therapy.

Diagnostic Confirmation First

Before treating, confirm the diagnosis with lesional skin biopsy showing leucocytoclastic vasculitis (leucocytoclasia, endothelial damage, perivascular fibrin deposition, red cell extravasation) 1. Perform a full vasculitis screen including C3 and C4 complement levels to distinguish normocomplementemic from hypocomplementemic disease—the latter carries a worse prognosis 1.

Treatment Algorithm by Disease Severity

Mild Disease (Skin-Limited, UVAS7 ≤7)

First-line: Non-sedating H1-antihistamines

• Start with cetirizine, desloratadine, fexofenadine, levocetirizine, loratadine, or mizolastine once daily 1
• Offer at least two different antihistamines as individual responses vary 1
• Escalate doses above manufacturer recommendations if inadequate response—this is common practice when benefits outweigh risks 1
• Consider adding H2-antihistamines for additional control 1

Second-line additions:

• Add sedating antihistamine at night (chlorphenamine 4-12 mg or hydroxyzine 10-50 mg) if sleep is affected 1
• Consider antileukotrienes for resistant cases 1

Moderate to Severe Disease (UVAS7 >7, Systemic Symptoms)

Oral corticosteroids are indicated for more prolonged treatment in urticarial vasculitis compared to ordinary urticaria 1. However, avoid long-term use due to side effects.

For refractory cases failing antihistamines and corticosteroids:

The most recent evidence (2025-2026) shows multiple effective options 2, 3, 4:

1. Omalizumab - High success rate, can be combined with cyclosporine (3 mg/kg/day) for rapid improvement within days 5, 2

2. Rituximab - Highest durability of remission among biologics, with long-lasting treatment-free responses 2, 3

3. IL-1 inhibitors (anakinra, canakinumab) - High success rates, particularly effective in refractory cases 2, 4

4. Conventional immunomodulators:

   • Dapsone - associated with long-lasting remission 2
   • Hydroxychloroquine 4
   • Mycophenolate mofetil - long-lasting treatment-free responses 2
   • Cyclosporine A 4

5. Emerging options:

   • JAK inhibitors (upadacitinib) - dramatic improvement reported in refractory cases 6
   • Tocilizumab - high success rate 2

Critical Considerations

Hypocomplementemic UV requires more aggressive management and multidisciplinary approach, as it carries worse prognosis with 5-year survival of 92% and 10-year survival of 83% 2. Screen for underlying systemic lupus erythematosus, malignancy, or infection 4.

Avoid aggravating factors: NSAIDs and aspirin should be avoided 1. Minimize overheating, stress, and alcohol 1.

Prognosis: Despite the chronic nature, eventual recovery is excellent for vasculitic urticarias 1.

Practical Pitfalls

• Don't confuse with chronic spontaneous urticaria—UV lesions last >24 hours and may leave purpura 1
• Don't undertreated with antihistamines alone in severe disease—biologics are typically used fifth-line but should be considered earlier in refractory cases 3
• Monitor for serious adverse events with biologics, particularly infections (17% in one cohort) 3
• Glucocorticoid discontinuation is achievable in only 34% of patients on biologics, so set realistic expectations 3